MIRA bids for SKNY

Florida-based MIRA Pharmaceuticals (Nasdaq: MIRA), a pharma company developing therapeutics for neurologic and neuropsychiatric disorders, has signed a binding letter of intent (LoI) to acquire privately held Delaware firm SKNY Pharmaceuticals.

The acquisition expands MIRA’s pipeline with SKNY-1, a pre-clinical stage oral therapeutic targeting the two leading causes of preventable death - obesity and smoking.

Also included in the transaction is a $5 million capital infusion - comprised of cash or equivalent consideration - into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1.